AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
Jab Sales Strong Despite Hurdles
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.
